Nasdaq
$42.38▼ 0.59%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.77BShares out 88.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
38- 10.14Pre-market26.10.14 10:49filed8-KKey event#●●●#●●●
Liquidia Corp
Liquidia has entered into a global settlement agreement with United Therapeutics (UTC) to resolve all six ongoing patent and litigation matters. Under the terms, Liquidia will pay a total of $380.7 million in installments, remove the PH-ILD indication from the YUTREPIA label, and cease all related marketing activities. The agreement ensures uninterrupted access to YUTREPIA for PAH patients, supported by the company's $396.1 million cash position as of September 30, 2026.…more
$42.38-0.59%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Overnight26.10.14 09:054Ownership
Liquidia Corp
Liquidia Corp insider Russell Schundler reported a change in his beneficial ownership of securities as of October 9, 2026. This filing serves as a Form 4 statement regarding the insider's equity holdings.…more
$42.38-0.59%vs prev closeView filingShare - 10.14Overnight26.10.14 09:044Ownership
Liquidia Corp
Insider Rajeev Saggar of Liquidia Corp reported a change in beneficial ownership of securities effective October 9, 2026. This filing serves as a standard disclosure of executive equity transactions and does not involve new share issuance or changes to the company's capital structure.…more
$42.38-0.59%vs prev closeView filingShare
37 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 21:02Bullish#●●●#●●●#●●●
Liquidia Settles Patent Dispute with United Therapeutics
Liquidia has resolved its long-standing patent litigation with United Therapeutics through a $380.7 million settlement, effectively removing a major legal overhang. The company plans to fund the settlement using existing cash and product sales without the need for additional capital raises.…more
$42.38-0.59%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.14Overnight26.10.14 14:11
●●●●●●●● ●●●●● ●●●●●●
Liquidia has reached a global settlement with United Therapeutics to resolve all pending patent litigation, effectively removing legal uncertainty. While the stock surged on the news, the company faces significant financial obligations from the agreed-upon settlement payments.…more
$42.38-0.59%vs prev closeShareBenzinga - 10.13After-hours26.10.14 06:52
●●●●●●●● ●●●●● ●●●●●●
Liquidia has agreed to remove the PH-ILD indication from its YUTREPIA label and cease promotion following a patent infringement ruling. The company will continue to advance its YUTREPIA and L606 clinical programs as previously planned.…more
$42.38-0.59%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report